Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

Inclusion Criteria:

* Patients are to be greater than 40 kg body weight.
* Patients must have adequate veins to provide intravenous access.
* Women who are not pregnant, lactating, or of childbearing potential. Lack of childbearing potential was defined as:

  * Being post-menopausal
  * Being surgically sterile
  * Practicing contraception
* Patients with childbearing potential had to have a negative serum human chorionic gonadotropin (HCG) upon entrance into the study.
* Patients must be willing to adhere to the protocol, and sign an Informed Patient Consent Form prior to entry into the study.
* Patients must not be on any other investigational device/drug treatment.
* Patients with the diagnosis of mycosis fungoides (MF) including a skin biopsy consistent with MF (atypical epidermotrophic or folliculocentric T-cells).
* Appropriate staging as IA, IB or IIA : T1 or T2 (patches or plaques) with measurable lesions.

  * IA patients must show evidence of a minor blood abnormality by morphology or laboratory assessment.
  * For IIA patients - clinically significant nodes (1.5 cm) must have lymph node biopsy showing dermatopathic nodes or no involvement.
* Patients must be willing and able to discontinue concomitant medications for MF.
* Patients currently taking the following drugs must discontinue medication prior to enrollment in the trial:

  * Psoralens and ultraviolet A (PUVA) or ultraviolet B (UVB) therapy - 4 weeks
  * Topical nitrogen mustard or other topical chemotherapy - 4 weeks
  * Bexarotene capsules or other systemic biologic agent - 3 weeks washout
  * High dose topical steroids, topical retinoids or immunotherapy - 2 week washout with 1% topical hydrocortisone
  * Oral steroids above 10 mg - 30 day washout, unless patient has Addison's disease or adrenal insufficiency
* Patients must be refractory to at least one of the standard therapies used to treat Stage IA, IB or IIA CTCL such as oral steroids, high-dose topical steroids, mechlorethamine (HN2), bexarotene, PUVA therapy, electron beam radiation, biological response or oral methotrexate.
* Patients must abstain from therapeutic sunbathing, tanning beds, etc. for the duration of the study.

Exclusion Criteria:

* Patients who have MF (T3 cutaneous tumors or T4 exfoliative erythroderma) Stage IIB - IVB, ie. no pathological node or visceral involvement.
* Patients who are unable to tolerate extracorporeal volume loss (e.g., severe cardiac disease or severe anemia or weight \< 40 kg).
* Patients with recent (within three months) deterioration of renal function who have a serum creatinine level greater than 3.0 mg/dL.
* Patients with lipemic plasma \> 500 ng/dL or uncontrolled diabetes.
* Patients with a history of liver damage (2.5 x normal ALT, AST) or porphyria.
* Patients with positive tests for HIV antibody, hepatitis C virus (HCV) antibody or hepatitis B surface antigen.
* Patients on oral prednisone therapy or full body or high potency topical steroids.
* Women who are pregnant or nursing a child.
* Patients with severe emotional, behavioral or psychiatric problems that, in the opinion of the investigator, would result in poor compliance with the treatment regimen.
* Patients who exhibit idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen compounds, heparin, or citrate.
* Patients with previous exposure to photopheresis therapy.
* Patients who use tanning beds or are receiving phototherapy.